Figure 5 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Imianowski CJ., Kuo P., Whiteside SK., von Linde T., Wesolowski AJ., Conti AG., Evans AC., Baird T., Morris BI., Fletcher NE., Yang J., Poon E., Lakins MA., Yamamoto M., Brewis N., Morrow M., Roychoudhuri R.
<p>Treg instability is induced by OX40/CD137 bispecific agonist (FS120m) and not anti-PD1 treatment. <b>A,</b> Representative plots showing the frequency of IFNγ<sup>+</sup> cells of CD4<sup>+</sup> Foxp3<sup>−</sup> Tconv cells and Foxp3<sup>+</sup> Tregs in the blood on day 18 after MC38 tumor implantation. <b>B,</b> Quantification and statistical analysis of data shown in <b>A</b>. Data were analyzed by ordinary one-way ANOVA (<b>B</b>) with Tukey correction for multiple comparisons. Bars and error are mean and SEM. *, <i>P</i> ≤ 0.05; ***, <i>P</i> ≤ 0.001; ****, <i>P</i> ≤ 0.0001.</p>